Exelixis, Inc. (EXEL)

Last Price: 26.80 (2020-09-18)

Company Description

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $967.78M
Net Income (Most Recent Fiscal Year) $321.01M
PE Ratio (Current Year Earnings Estimate) 59.21
PE Ratio (Trailing 12 Months) 30.27
PEG Ratio (Long Term Growth Estimate) 1.57
Price to Sales Ratio (Trailing 12 Months) 8.34
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 4.54
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 24.85
Pre-Tax Margin (Trailing 12 Months) 34.90%
Net Margin (Trailing 12 Months) 28.21%
Return on Equity (Trailing 12 Months) 16.40%
Return on Assets (Trailing 12 Months) 14.68%
Current Ratio (Most Recent Fiscal Quarter) 9.77
Quick Ratio (Most Recent Fiscal Quarter) 9.66
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) 2.51
Book Value per Share (Most Recent Fiscal Quarter) $5.55
Earnings per Share (Most Recent Fiscal Quarter) $0.21
Earnings per Share (Most Recent Fiscal Year) $1.02
Diluted Earnings per Share (Trailing 12 Months) $0.89
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 309.00M
Free Float 295.09M
Market Capitalization $8.32B
Average Volume (Last 20 Days) 1.88M
Beta (Past 60 Months) 1.41
Percentage Held By Insiders (Latest Annual Proxy Report) 4.50%
Percentage Held By Institutions (Latest 13F Reports) 81.62%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%